Yuchun Wei | Medicine and Health Sciences | Best Researcher Award

Assoc. Prof. Dr. Yuchun Wei | Medicine and Health Sciences | Best Researcher Award

Shandong Cancer Hospital China

Dr. Yuchun Wei is a leading Chinese physician-scientist in the field of oncology and nuclear medicine, currently working at the Shandong Cancer Hospital in Jinan, China. Born on November 22, 1987, she has contributed significantly to developing innovative imaging techniques for cancer diagnosis, staging, and individualized treatment planning. With deep expertise in PET/CT imaging biomarkers, she is committed to advancing precision oncology. 📡🧬

Profile

Scopus

Orcid

🎓 Education

Dr. Wei pursued her academic journey with a strong foundation in both Western and traditional Chinese medicine:

  • Ph.D. in Oncology from Shandong University (2018–2022), mentored by Academician Jinming Yu 🎓
  • Master’s in Oncology from Jinan University (2013–2016), under Prof. Shuanghu Yuan 🔬
  • Bachelor’s in Traditional Chinese and Western Clinical Medicine from Shandong University of Traditional Chinese Medicine (2007–2012) 🌿

đź’Ľ Professional Experience

Dr. Wei currently serves as a radiotherapy physician at Shandong Cancer Hospital (2017–present). She has also held several administrative and research leadership roles:

  • Deputy Director, MDT Quality Management Office (2021–2022)
  • Assistant Director, Radioimmunity and Molecular Imaging Room (2020–2021)
    Her clinical expertise is complemented by her operational leadership in multidisciplinary cancer care. 🏥⚕️

🔬 Research Interests

Her research revolves around novel imaging techniques, especially FAPI-based PET/CT imaging, with a focus on early detection, prognosis prediction, and therapy monitoring for cancers such as lung, esophageal, and cervical. Her goal is to refine personalized cancer treatment through quantitative imaging biomarkers. 🔍📊

🏆 Awards & Honors

Dr. Wei has been nominated for multiple research and innovation awards in recognition of her work in molecular imaging and radiation oncology. Her studies have earned significant visibility in top-tier journals (JCR Q1), and she is regarded as a rising star in clinical translational imaging. 🌟

📚 Publications Top Notes: 

Dr. Wei has authored and co-authored over 17 high-impact peer-reviewed papers, most of which appear in JCR Q1 journals. Here are her key publications with direct links and citation highlights:

FAPI Compared with FDG PET/CT for Lung Cancer Diagnosis
Radiology, 2023, IF: 19.7 | Cited by: 33

18F-FAPI PET/CT in Esophageal SCC Response Prediction
J Nucl Med, 2024, IF: 9.1 | Cited by: 12

Early Detection of Radiation-Induced Myocardial Damage
Eur J Nucl Med Mol Imaging, 2023, IF: 10.057 | Cited by: 40

18F-FAPI PET/CT Response in Chemoradiotherapy for ESCC
J Nucl Med, 2023, IF: 11.082 | Cited by: 25

Biodistribution and Targeting of 18F-FAPI-04
Eur J Nucl Med Mol Imaging, 2022, IF: 10.057 | Cited by: 37

Differentiating Lung Cancer Types via PET/CT
Eur J Nucl Med Mol Imaging, 2022, IF: 10.057 | Cited by: 31

Baseline Angiogenesis in NSCLC Prognosis
J Transl Med, 2022, IF: 8.44 | Cited by: 19

Differentiating Inflammatory Lung Lesions with FAPI
Eur Radiol, 2023, IF: 5.9 | Cited by: 10

Comparison Study in Mouse Model using PET Imaging
Sci Rep, 2016, IF: 5.228 | Cited by: 50

Radiation-Induced Lung Damage Model in Rats
Front Oncol, 2022, IF: 5.738 | Cited by: 14

Stefano Stefano | Medicine and Health Sciences | Best Researcher Award

Dr. Stefano Stefano | Medicine and Health Sciences | Best Researcher Award

MD, Specializing in Rheumatology (4th year) University of Bari, Rheumatology Unit Italy

👨‍⚕️ Stefano Stano is a 4th-year MD specializing in Rheumatology at the University of Bari “Aldo Moro,” Polyclinic Hospital. His passion for rheumatology and medical research drives his active involvement in clinical and translational studies, focusing on systemic sclerosis, Sjögren’s disease, and other connective tissue disorders. Stefano aspires to pursue a Ph.D. and build an academic career contributing to advancements in rheumatology.

Profile

Orcid

Education

🎓 Stefano holds an MD and is in the final year of his specialization in Rheumatology at the University of Bari “Aldo Moro.” His academic journey is marked by consistent dedication to both theoretical and practical aspects of his field.

Experience

🩺 With over 5 years of daily involvement in research and clinical practice, Stefano balances laboratory experiments and outpatient assessments. His hands-on approach to rheumatic diseases has honed his skills in addressing complex cases and conducting in-depth studies.

Research Interests

🔬 Stefano’s research is centered on rheumatic diseases, with a special emphasis on systemic sclerosis and Sjögren’s syndrome. He is particularly interested in exploring translational approaches that bridge laboratory findings with clinical applications.

Awards

🏅 Stefano aims to secure the Best Researcher Award in recognition of his efforts in advancing rheumatological research. His dedication and achievements position him as a strong contender.

Publications Top Notes: 

📚 Stefano’s contributions to the field are evidenced by his peer-reviewed publications, which include studies on targeted therapies, systemic sclerosis, and rheumatoid arthritis. His works have been published in reputed journals:

Cacciapaglia F, et al. (2022). Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis. J Pers Med. Read here.

Fornaro M, et al. (2022). Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10-year study from the BIOPURE registry. Eur J Clin Invest. Read here.

Cacciapaglia F, et al. (2022). Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review. Journal of Scleroderma and Related Disorders. Read here.

De Luca G, et al. (2024). Rituximab retention rate in systemic sclerosis: a long-term real-life multicenter study. Rheumatology. Read here.

Iannone C, et al. (2024). Pulmonary and extra-pulmonary effects of lung transplantation in systemic sclerosis. Rheumatology. Read here.

De Lorenzis E, et al. (2024). Long-term retention rate, adverse event temporal patterns, and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. Rheumatology. Read here.

Fornaro M, et al. (2024). Effectiveness of tapering rituximab dose in idiopathic inflammatory myopathies: Real-world data from a monocentric study. Joint Bone Spine. Read here.

Stano S, et al. (2024). Anti-aquaporin-5 and anti-poly-U-binding-factor-60kDa protein antibodies in primary Sjögren’s disease patients: Preliminary data and correlation with disease activity indices. Clin Exp Rheumatol. Read here.

Cacciapaglia F, et al. (2024). Modulation of IL-6 receptor/STAT3 downstream signaling in rheumatoid arthritis patients. Exp Mol Pathol. Read here.